About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

52.90 +1.16 (+2.24%)
Official Closing Price Updated: 7:00 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,436,256
Open 51.95
Bid (Size) 52.91 (2)
Ask (Size) 52.96 (2)
Prev. Close 51.74
Today's Range 51.61 - 52.97
52wk Range 39.35 - 58.06
Shares Outstanding 2,222,113,553
Dividend Yield 4.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb executive as CEO. The company aims to extend its cash runway into 2027. 
Via Benzinga

Performance

YTD
+0.27%
+0.27%
1 Month
+4.71%
+4.71%
3 Month
+30.78%
+30.78%
6 Month
+0.30%
+0.30%
1 Year
-8.56%
-8.56%

More News

Read More
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Via The Motley Fool
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Via Benzinga
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
From Prime Medicine, Inc.
Via GlobeNewswire
NYSE:BMY Shows Potential for a Breakout.
Via Chartmill
What Analysts Are Saying About Bristol-Myers Squibb Stock
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
Via The Motley Fool
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
From Bristol Myers Squibb
Via Business Wire
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
From Bristol Myers Squibb
Via Business Wire
14 Stocks Gain Momentum As August Inflation Comes In Below Expectations
Via Benzinga
Topics Economy
Exposures Interest Rates
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Via Benzinga
Exposures Product Safety
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Wall Street On Wait-And-Watch Mode Ahead Of Inflation Data, Bitcoin Holds Above 65.5K: Analyst Says Volatility Ahead Providing Better Entry Point Into Long-term Bull Market
Via Benzinga
Topics Economy
Exposures Interest Rates
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Via Investor's Business Daily
Exposures Product Safety
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Via Benzinga
Exposures Product Safety
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Via Benzinga
Exposures Product Safety
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Via Investor's Business Daily
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
Via Benzinga
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.